---
title: Case Study - Synthesis & Characterization of Trastuzumab-Based ADCs Using Fluorescent & Cytotoxic Payloads
description: Case Study - Synthesis & Characterization of Trastuzumab-Based ADCs Using Fluorescent & Cytotoxic Payloads
image: https://info.edifydigitalmedia.com/hubfs/CMP%20images/Eurofins%20CMP%20-%2016.06.25/DDW_ADC%20Case%20Study%20Mockup_v1.jpg
---

[![DDW-Logo](https://info.edifydigitalmedia.com/hs-fs/hubfs/DDW-Logo.png?width=239&height=121&name=DDW-Logo.png "DDW-Logo")](https://www.edifydigitalmedia.com/)

![Eurofins CMP Landing Page Banner - 16.06.25](https://info.edifydigitalmedia.com/hs-fs/hubfs/CMP%20images/Eurofins%20CMP%20-%2016.06.25/Eurofins%20CMP%20Landing%20Page%20Banner%20-%2016.06.25.png?width=1425&height=400&name=Eurofins%20CMP%20Landing%20Page%20Banner%20-%2016.06.25.png "Eurofins CMP Landing Page Banner - 16.06.25")

# Case Study

# Synthesis & Characterization of Trastuzumab-Based ADCs Using Fluorescent & Cytotoxic Payloads

 

![DDW\_ADC Case Study Mockup\_v1](https://info.edifydigitalmedia.com/hubfs/CMP%20images/Eurofins%20CMP%20-%2016.06.25/DDW_ADC%20Case%20Study%20Mockup_v1.jpg "DDW_ADC Case Study Mockup_v1")

Delve into our case studies on ADC Synthesis, Development, and Characterization, where we reveal how:

- Trastuzumab-based ADCs with multiple payload linkers demonstrated specific, targeted functional activity.
- Flow cytometry and internalization assays confirmed antigen targeting and cellular uptake.
- Cytotoxicity assays revealed nanomolar IC50s only in HER2+ cell lines, confirming ADC efficacy and specific killing.

Brought to you by 

![DISCOVERX\_eurofins\_Logo](https://info.edifydigitalmedia.com/hs-fs/hubfs/CMP%20images/Eurofins%20CMP%20-%2016.06.25/DISCOVERX_eurofins_Logo.jpg?width=201&height=106&name=DISCOVERX_eurofins_Logo.jpg)

 

### Download Case Study

## Copyright 2025 Drug Discovery World. All Rights Reserved Privacy Policy & Cookies | Contact | Terms & Conditions